Ontology highlight
ABSTRACT:
SUBMITTER: DeFilipp Z
PROVIDER: S-EPMC7358778 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
DeFilipp Zachariah Z Ancheta Richard R Liu Ying Y Hu Zhen-Huan ZH Gale Robert Peter RP Snyder David D Schouten Harry C HC Kalaycio Matt M Hildebrandt Gerhard C GC Ustun Celalettin C Daly Andrew A Ganguly Siddhartha S Inamoto Yoshihiro Y Litzow Mark M Szer Jeffrey J Savoie Mary Lynn ML Hossain Nasheed N Kharfan-Dabaja Mohamed A MA Hamadani Mehdi M Reshef Ran R Bajel Ashish A Schultz Kirk R KR Gadalla Shahinaz S Gerds Aaron A Liesveld Jane J Juckett Mark B MB Kamble Rammurti R Hashmi Shahrukh S Abdel-Azim Hisham H Solh Melhem M Bacher Ulrike U Lazarus Hillard H Olsson Richard R Cahn Jean-Yves JY Grunwald Michael R MR Savani Bipin N BN Yared Jean J Rowe Jacob M JM Cerny Jan J Chaudhri Naeem A NA Aljurf Mahmoud M Beitinjaneh Amer A Seo Sachiko S Nishihori Taiga T Hsu Jack W JW Ramanathan Muthalagu M Alyea Edwin E Popat Uday U Sobecks Ronald R Saber Wael W
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20191025 3
It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to t ...[more]